Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
Shift Pharmaceuticals, CMTA Partner on ASO Treatment for CMT1A
Shift Pharmaceuticals, CMTA Partner on ASO Treatment for CMT1A GLENOLDEN, PENNSYLVANIA, USA, NOVEMBER 3, 2022 — Shift Pharmaceuticals, a privately held company that is developing antisense oligonucleotides (ASOs) to treat…
Consensus_Statement_on_Surgical_Treatment_of_CMT
CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C
…urgent need for new treatments for these patients.” We celebrate this encouraging news from Actio Biosciences and look forward to the continued progress in bringing effective treatments to those affected…
CMTA’s $450K Investment Targets New Approach to Treatment for Patients with CMT1A and CMT1B
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $450K into a new scientific approach…
CMT1A Ionis Press Release
New Research Shows Promise for CMT Progressive Neuromuscular Disease Potential treatment offers hope for over 2.8 million affected worldwide Glenolden PA, December 4, 2017—A new paper published December 4th on…
Data Shows Benefit with PXT3003 in Patients with CMT1A
…treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with encouraging topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and…
A Cure for Caroline and Other CMT Stories
Caroline’s journey with a rare and serious form of CMT began when she was just 9 months old. Today, a cure for Caroline may open the door to treatments and…
Webinar Recordings
…spent the last decade specializing in treatment of adults with acquired neurological impairments. She is certified in neuro-developmental treatment and the use of physical agent modalities. She has specialty training…
CMTA-STAR Partner Applied Therapeutics Presents 24-Month CMT-SORD Data at PNS 2025
…Annual Meeting of the Peripheral Nerve Society (PNS). The findings highlight encouraging signs of sustained clinical benefit and reflect continued momentum in the effort to advance treatments for all forms…
What’s New in CMT Research and Care? A 2025 Update Published by CMTA-STAR Advisory Board Member Davide Pareyson, MD
…proper care and treatment planning. Visit CMTA’s Diagnosing CMT page to learn more. Comprehensive Care: Managing CMT Today While there are no FDA-approved treatments for CMT, CMT specialists continue refining…